희귀 신장 질환 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Rare Kidney Diseases Treatment Market size is expected to reach USD 6.59 Billion in 2034 from USD 3.82 Billion (2025) growing at a CAGR of 6.23% during 2026-2034.

The Global Rare Kidney Diseases Treatment Market is witnessing notable growth driven by increasing awareness and improved diagnosis of rare renal disorders. Conditions such as focal segmental glomerulosclerosis and atypical hemolytic uremic syndrome require specialized therapies. Advancements in genetic testing and biomarker identification are enabling earlier and more accurate diagnoses. Rising investments in orphan drug development are further supporting market expansion.

Key growth drivers include supportive regulatory frameworks that provide incentives for orphan drug approvals. Biopharmaceutical companies are focusing on targeted therapies and biologics to address unmet medical needs. Increasing patient advocacy and funding for rare disease research are accelerating clinical trials. Additionally, improved healthcare access in developed countries is enhancing treatment availability.

Future prospects are promising as personalized medicine and gene therapies continue to evolve. Emerging markets are gradually improving rare disease management infrastructure. Strategic partnerships between research institutions and pharmaceutical firms will accelerate innovation. As awareness and diagnostic capabilities expand globally, the rare kidney diseases treatment market is expected to experience sustained and meaningful growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Enzyme Replacement Therapy
• Monoclonal Antibodies
• Others

By Indication

• Fabry Disease
• Atypical Hemolytic Uremic Syndrome
• Lupus Nephritis
• Nephropathic Cystinosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

COMPANIES PROFILED

• Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals Inc, Amicus Therapeutics Inc, Shire Takeda Pharmaceutical Company Limited, Sanofi, Advicenne, Alexion Pharmaceuticals Inc, Horizon Therapeutics plc, Otsuka Pharmaceutical Co Ltd, Reata Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Enzyme Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Fabry Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Atypical Hemolytic Uremic Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lupus Nephritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nephropathic Cystinosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RARE KIDNEY DISEASES TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Calliditas Therapeutics AB
  • 9.2.2 GSK Plc
  • 9.2.3 Aurinia Pharmaceuticals Inc
  • 9.2.4 Amicus Therapeutics Inc
  • 9.2.5 Shire (Takeda Pharmaceutical Company Limited)
  • 9.2.6 Sanofi
  • 9.2.7 Advicenne
  • 9.2.8 Alexion Pharmaceuticals Inc
  • 9.2.9 Horizon Therapeutics Plc
  • 9.2.10 Otsuka Pharmaceutical Co. Ltd
  • 9.2.11 Reata Pharmaceuticals Inc